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Over the past decade, major advances in clinical neu-rology (eg, stroke units and neuroimaging techniques) 
have distinctively improved timely diagnosis and manage-
ment of stroke and its major subtypes.1 However, it remains 
unclear whether this progress translates into improved sur-
vival for both hemorrhagic and ischemic stroke in the ge-
neral population.
Survival following stroke is an important indicator in mon-
itoring stroke burden.2 Several studies have observed decline 
in mortality after any stroke.3–6 However, up-to-date country-
specific survival data by stroke-subtype are scarce. Although 
there is agreement on the increased risk of mortality following 
a stroke, recent data on time trends in survival in the general 
population, especially for hemorrhagic stroke, are limited.
Prospective studies provide an opportunity for pre-
cise monitoring of the burden related to stroke-subtypes 
in unselected samples of patients. This is in contrast to 
hospital-based data where the following inherent limita-
tions exist: (1) selection bias related to indication for ad-
mission according to stroke severity and prognosis; (2) 
potential differential access to specialized stroke units; and 
(3) variation between centers in quality of in-patients care 
and services provided. These factors influence outcomes of 
patients with stroke and therefore hospitalizations data may 
not reflect the real burden of the disease in the population.
Regular monitoring of trends in survival by stroke-subtype 
is necessary to monitor the disease burden at a population 
level.7 In this report, we characterized temporal trends in sur-
vival following hemorrhagic or ischemic stroke using a large 
population-based sample of middle-aged and elderly people 
over 20 years of follow-up.
Background and Purpose—The introduction of stroke units and the implementation of evidence-based interventions have 
been a breakthrough in the management of patients with stroke over the past decade. Survival following stroke is an 
important indicator in monitoring stroke burden. Recent data on survival by stroke subtype in the general population is 
scarce. We assessed (1) recent temporal time trends in survival; (2) age-standardized death rates; (3) survival probabilities 
at 6 months, 1, 2, and 3 years following first hemorrhagic or ischemic stroke.
Methods—Within the population-based Rotterdam Study between 1991 and 2015, we assessed time trends in survival 
among 162 with first-ever hemorrhagic and 988 patients with first-ever ischemic stroke across 3 time periods (1991–
1998; 1999–2007; 2008–2015) using time-varying Cox regression model and calculated age-standardized death rates 
according to the European 2010 census population.
Results—In the hemorrhagic stroke group, a total of 144 deaths occurred during 386 person-years. Following a hemorrhagic 
stroke, we observed similar mortality rates over the years with 30 per 100 person-years in 2015 compared with 25/100 
person-years in 1991. Similarly, compared with the earliest study period (1991–1998), mortality rates remained 
unchanged in the latest study period (2008–2015; hazard ratio, 0.97 [95% CI, 0.61–1.57]; P=0.93). In the ischemic 
stroke group, a total of 711 deaths occurred during 4897 person-years. We observed a decline in mortality rates in 2015 
(11 per 100 person-years) compared with 1991 (29/100 person-years). This translated to favorable trends in the latest 
study period 2008 to 2015 (hazard ratio, 0.71 [95% CI, 0.56–0.90]; P<0.01).
Conclusions—Survival following ischemic stroke has improved over the past decade, while no change was observed in 
survival following hemorrhagic stroke.   (Stroke. 2020;51:824-829. DOI: 10.1161/STROKEAHA.119.027198.)
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Methods
Study Settings
The Rotterdam Study
This study included participants from the Rotterdam Study, a pro-
spective community-based cohort study.8 In 1990, residents aged 55 
years and older residing in Ommoord, a district of Rotterdam, the 
Netherlands, were invited to participate in the study. Of 10 215 invited 
inhabitants, 7983 agreed to participate in the baseline examinations. 
In 2000, 3011 participants (of 4472 invitees) who had reached 55 
years of age or moved into the study district since the start of the 
study were added to the cohort. In 2006, a further extension of the 
cohort was started in which 3932 participants, of 6057 invited, aged 
at least 45 years living in Ommoord were included. Follow-up exami-
nations take place every 3 to 4 years. For the purpose of the present 
study, we excluded patients with unspecified stroke diagnosis.
Informed Consent and Ethics Approval
The Rotterdam Study has been approved by the medical ethics com-
mittee of the Erasmus MC (registration number MEC 02.1015) and 
by the Dutch Ministry of Health, Welfare and Sport (Population 
Screening Act WBO, license number 1071272-159521-PG). When 
visiting the study center, participants provided written informed con-
sent to participate in the study and to have their information obtained 
from treating physicians. Requests to access the dataset from qual-
ified researchers trained in human subject confidentiality protocols 
may be sent to Department of Epidemiology, Erasmus MC University 
Medical Center at f.vanrooij@erasmusmc.nl.
Stroke Assessment and Follow-Up
Stroke was defined according to the World Health Organization criteria 
as a syndrome of rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function, with symptoms lasting 24 hours or 
longer or leading to death, with no apparent cause other than of vascular 
origin.8–10 History of stroke at baseline was assessed during baseline in-
terview and verified by reviewing medical records. After enrollment, 
participants were continuously monitored for incident stroke through 
automated linkage of the study database with files from general practi-
tioners. Nursing home physicians’ and general practitioner files of par-
ticipants who moved out of the district were checked on a regular basis 
as well. Additional information was obtained from hospital records. 
Potential strokes were reviewed by research physicians and verified by 
an experienced neurologist. Stroke subtype (hemorrhagic or ischemic), 
location, cause, and other stroke specific characteristics were based on 
neuroimaging reports and hospital discharge letters. If these were ab-
sent, then the stroke subtype was classified as unspecified. This clas-
sification corresponded with International Classification of Diseases 
Tenth Version codes I61, I63, and I64. Participants could contribute 
person-years to the follow-up that is, from date of first stroke diagnosis 
until death, loss to follow-up, or end of study period (January 1, 2016), 
whichever came first. Follow-up was virtually complete (95.8%).
Mortality
Information on vital status of participants was obtained on a weekly 
basis via municipal population registries and through general prac-
titioners’ and hospitals’ databases. Events were coded according to 
the International Classification of Diseases Tenth Version by 2 inde-
pendent research physicians. All-cause mortality was defined as par-
ticipants who died from any cause during the total follow-up period, 
which was completed until January 1, 2016.
Statistical Analysis
Baseline characteristics were summarized as median (interquartile 
range) for continuous variables and frequencies and percentages for 
categorical variables. Two types of analysis were undertaken. First, 
time-varying Cox proportional hazards regression analysis was 
used to assess mortality rates following first-ever hemorrhagic or is-
chemic stroke across the following 3 main study periods: 1991 to 
1998, 1999 to 2007, and 2008 to 2015. Models were adjusted for sex 
and age at stroke diagnosis. Models fit was assessed based on Akaike 
Information Criterion. Second, age-standardized mortality rates 
per 100 person-years stratified by stroke subtype were calculated 
according to the age distribution in the standard European population 
in 2010 using 5-year age groups.11 Individuals who died on the same 
day of their stroke diagnosis contributed 1 day of follow-up in the 
analysis. We further assessed survival probabilities at 6 months, 1, 2, 
and 3 years in both groups and in a control group of stroke-free cases 
matched on age and sex to the overall stroke group. Analyses were 
performed using the Stata v15.0 (StataCorp, College Station, TX).
Results
Population Characteristics
Hemorrhagic Stroke
Over the study period between 1991 and 2015, among 162 
hemorrhagic strokes, a total of 144 deaths occurred during 386 
person-years. In the hemorrhagic group, 59 % were women, 
median age at time of stroke diagnosis was 79 (72–85) years, 
and median age at death was 82 (77–87) years (Table 1).
Among the cases for which a cause was specified (n=62 
[38%]), anticoagulant-related hemorrhagic stroke and amy-
loid angiopathy represented the majority of cases (n=36), fol-
lowed by hypertension (n=11). The majority of cases with an 
identified location were lobar (n=49) or deep (n=25; Figure 1).
Ischemic Stroke
Over the study period between 1991 and 2015, among 988 
ischemic strokes, a total of 711 deaths occurred during 4897 
person-years. In the ischemic stroke group, 56% were women, 
median age at time of stroke diagnosis was 78 (72–84) years, 
and median age at death was 84 (79–89) years (Table 1).
Time Trends in Survival Following Hemorrhagic  
Stroke
Absolute death counts and age-standardized mortality rates 
remained unchanged over the study period following hemor-
rhagic stroke (Figure 1). In adjusted Cox proportional hazards 
models, compared with the earliest study period (1991–1998), 
Table 1. Descriptive Characteristics of the Population
Hemorrhagic Stroke Ischemic Stroke
N 162 988
Age at stroke date, y 79.6 (12.8) 78.2 (11.7)
Women 96 (59.3) 556 (56.3)
BMI, kg/m2 26.1 (4.9) 26.9 (4.4)
Cholesterol, mmol/L 5.8 (1.2) 5.9 (1.6)
Diabetes mellitus type 2 30 (28.6) 192 (29.1)
Hypertension 123 (82.6) 767 (83.9)
Smoking
  Current 32 (21.2) 232 (25.0)
  Former 75 (49.7) 387 (41.7)
  Never 44 (29.1) 308 (33.2)
Categorical: number (percentage). Continuous: median (interquartile range); for 
all characteristics (except age at stroke diagnosis and sex), the values were derived 
from the visit to the research center that was before the date of stroke; missing 
covariate data in the hemorrhagic and ischemic stroke groups were as follows: 
BMI (8%, 10%); cholesterol (10%, 9%); DM (35%, 33%); hypertension (8%, 7%); 
smoking (7%, 6%); reasons for missing covariate data: (1) participants did not visit 
the research center before their first stroke date (2) or data were missing at baseline 
and subsequent visits. BMI indicates body mass index; and  DM, diabetes mellitus.
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mortality rates following hemorrhagic stroke remained un-
changed in 1999 to 2007 (adjusted hazard ratio, 0.88 [95% CI, 
0.56–1.38]) and 2008 to 2015 (adjusted hazard ratio, 0.98 [95% 
CI, 0.61–1.57]; Table 2).
Time Trends in Survival Following Ischemic Stroke
The absolute death counts continued to increase with the aging 
of our population. A steady decline was observed overtime in 
the age-standardized mortality rates over the study period fol-
lowing ischemic stroke (Figure 2). Mortality rates following 
ischemic stroke declined in the later study periods in 1999 
to 2007 (adjusted hazard ratio, 0.85 [95% CI, 0.67–1.06]) 
and 2008 to 2015 (adjusted hazard ratio, 0.71 [95% CI, 0.56–
0.90]) compared with the earliest study period (1991–1998; 
Table 2).
Survival Probabilities Following Hemorrhagic or  
Ischemic Stroke
In the hemorrhagic stroke group, survival probabilities were 
as follows: 6 months (36% [95% CI, 28–43]), 1 year (34% 
[95% CI, 27–41]), 2 years (31% [95% CI, 24–38]), and 3 
years (27% [95% CI, 20–33]).
In the ischemic stroke, estimates were as follows: at 6 
months (81% [95% CI, 78–83]), 1 year (76% [95% CI, 73–
78]), 2 years (68% [95% CI, 65–71]), and 3 years (61% [95% 
CI, 58–64]).
Among the age- and sex-matched stroke-free con-
trols, survival probabilities were: 96% (95% CI, 94–97) 
at 6 months; 93% (95% CI, 92–95) at 1 year, 87% (95% 
CI, 85–89) at 2 years, and 82% (95% CI, 80–84) at 3 years 
(Figure 3). Survival probabilities in the control group 
remained high over the 25 years of follow-up (Figure I in the 
online-only Data Supplement).
Discussion
We observed favorable trends in survival following ischemic 
stroke. In contrast, mortality rates following hemorrhagic 
stroke remained high.
There are several factors that could have contributed to 
the observed favorable trends in survival following ischemic 
stroke in our study and the observed decline in mortality 
after any stroke in other settings.3,5,6,12 First, the introduction 
of stroke units providing timely acute medical management 
and dedicated rehabilitation.13,14 Furthermore, among eli-
gible patients, thrombolytic therapy within the first 6 hours 
has been associated with less death and dependence despite a 
relative increase in symptomatic intracranial hemorrhage.15 In 
addition, reduction of in-hospital mortality has been reported 
among patients with shorter time to endovascular-reperfusion 
therapy in routine clinical practice.16 Second, the availability 
of high-quality evidence and guidelines on best practices in 
the acute phase, particularly on postacute stroke management 
in recent years.17 Third, the improved control of risk factors 
and timely counseling after stroke.18
Recent reports further emphasize the role played by 
stroke units and advances in stroke care in reducing stroke-
related mortality and case fatality.13,14,19 In the Netherlands, 
major advances in stroke care were introduced since mid-
nineties and continued to be widely implemented after 2000 
including stroke units, thrombolytic therapy, and stroke pre-
vention guidelines.19–21
Despite this decline in mortality rates, the absolute num-
bers of deaths after stroke and the numbers of patients in need 
of care and intensive treatment is unlikely to diminish in the 
near future, owing to the rise in aging populations globally.12 
In fact, the favorable trends observed after ischemic stroke 
will likely gradually translate to a greater accumulated burden 
of disability and stroke-related dependency.3,22–24
A majority of patients with stroke suffer from one or more 
disability after recovery including hemiparesis (≈50%), cog-
nitive deficits (46%), aphasia (19%), depression (35%), and 
limitations with walking unassisted (30%).25 Several reports 
showed an increase in long-term institutionalization, in-patient 
rehabilitation services, support services after discharge, and 
informal care giving among stroke survivors.3,23–25
Stroke is ranked as one of the most expensive diseases 
in the Netherlands.26 The burden of stroke-related disability 
and the associated costs are expected to continue to increase 
in aging populations. Beyond professional care giving and 
institutionalization costs, data from the American Heart 
Association showed that costs of informal care giving alone 
Figure 1. Location of hemorrhagic stroke.
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constitute more than half of the total costs of cardiovascular 
disease combined, with an estimated 31$ billion in 2015 and 
66$ billion in 2035.27 Hence, reducing stroke-related disa-
bility is becoming an increasingly fundamental target to sig-
nificantly reduce stroke burden in high-risk populations.12
In contrast to ischemic stroke, a fewer successful thera-
peutic options exist for hemorrhagic stroke.28 Poor outcomes 
following hemorrhagic stroke are linked to the complications 
that arise shortly following onset. Hematoma expansion and 
early deterioration are common within the first few hours. 
Further, hematoma volume, deep location, and extension of 
bleeding into the ventricular system have been linked to poor 
neurological outcomes.28,29
To date, no successful phase 3 clinical trials have been 
documented for therapeutic options among hemorrhagic 
stroke survivors. This research gap highlights the impor-
tance of targeting complications during the acute phase of 
the disease, given that patients are highly likely to be un-
stable shortly after onset. Current evidence supports admit-
ting hemorrhagic stroke survivors to a dedicated stroke unit 
rather than general intensive-care unit.30 This is particu-
larly essential given the lack of therapeutic options; hence, 
prevention or early detection of complications could be the 
most effective approach to improve outcomes after hemor-
rhagic stroke.31
Recent estimates from the STICH trial (Early Surgery 
Versus Initial Conservative Treatment in Patients With 
Spontaneous Supratentorial Lobar Intracerebral Haematomas) 
showed improved 6-month mortality rates in patients who re-
ceived early surgical hematoma evacuation within 12 hours of 
randomization plus medical treatment (18%) compared with 
initial medical treatment alone (24%).32 Data of the MISTIE 
trial (Safety and Efficacy of Minimally Invasive Surgery Plus 
Alteplase in Intracerebral Haemorrhage Evacuation) showed 
no difference  at 6 months in the proportion of patients with 
modified Rankin Scale score of 6 between minimally invasive 
surgery plus alteplase compared with standard medical care.33 
Although these interventions show promise in selected sam-
ples of patients in the setting of clinical trials, these advances 
are not yet reflected in the setting of the general population. 
In our study, 6-month mortality rate in the hemorrhagic stroke 
group was 64%, and comparable estimates were reported from 
the Swedish stroke register with ≈60% mortality rate at 12 
Table 2. Cox Regression Model of Time to Death Following Hemorrhagic or Ischemic Stroke
Hemorrhagic Strokes, N=162 Ischemic Strokes, N=988
Deaths, n Person-Years* aHR† (95% CI) P Value Deaths, n Person-Years aHR† (95% CI) P Value
Study period
  1991–1998 30 38 … … 110 635 … …
  1999–2007 60 163 0.88 (0.56–1.38) 0.60 294 2031 0.85 (0.67–1.06) 0.16
  2008–2015 54 184 0.98 (0.61–1.57) 0.93 307 2230 0.71 (0.56–0.90) <0.01
*aHR indicates adjusted hazard ratio.
†Person-years represent the unit for the population in each calendar period in a time-varying fashion.
‡Models are adjusted for age at stroke diagnosis and sex.
Figure 2. Absolute death counts and age standardized death rates per 100 person-years following hemorrhagic or ischemic stroke. P value test for trend 
across calendar year.
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months among those with functional dependence and 42% 
among all intracerebral hemorrhage cases.22
The decline in mortality after ischemic stroke in our 
study aligns with the decline of coronary heart disease 
mortality observed in the Netherlands and in other coun-
tries.34,35 Cardiovascular disease is a leading cause of death 
in the Rotterdam study population and nationwide in the 
Netherlands.36–40 In 2017, ischemic heart disease and stroke 
ranked as first and third causes of years of life lost world-
wide.41,42 Collectively, these observations highlight the need 
for continuous efforts targeted toward prevention of stroke 
and ischemic heart disease, particularly in the setting of eld-
erly populations.
Our study has several limitations. Our sample included a 
proportion of unspecified strokes and thus were not included 
in the analysis. This could have resulted in underestimation of 
mortality rates; however, the consistency in trends among the 
classified cases is reassuring and the exclusion of those cases 
is not uncommon in stroke-subtype investigations.43 Further, 
the limited power among cases with identified location or 
cause in the hemorrhagic stroke group hindered conducting 
a stratified or subgroup analysis. However, among the clas-
sified cases, the majority were of lobar location or related to 
anticoagulants and amyloid angiopathy. Similar observations 
have been reported from the United Kingdom and the United 
States.44,45 Last, our sample is restricted to stroke survivors 
among the elderly, thus cannot be extrapolated to younger 
stroke survivors.
Alongside the long follow-up duration and state-of-the-art 
clinical examinations, a key strength of our study includes the 
unselected sample of participants who were followed up pro-
spectively, thus avoiding common biases related to institution 
or patient selection. These factors all together provide a close 
reflection of the current disease burden in the population.
Conclusions
In this report, we observed marked improvement in survival 
following ischemic stroke since early 2000s, in contrast no 
improvement in survival following hemorrhagic stroke was 
observed.
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